Literature DB >> 29261405

Evaluation of Aminoglycoside and Carbapenem Resistance in a Collection of Drug-Resistant Pseudomonas aeruginosa Clinical Isolates.

Selina Y L Holbrook1, Sylvie Garneau-Tsodikova1.   

Abstract

Pseudomonas aeruginosa, a Gram-negative bacterium, is a member of the ESKAPE pathogens and one of the leading causes of healthcare-associated infections worldwide. Aminoglycosides (AGs) are recognized for their efficacy against P. aeruginosa. The most common resistance mechanism against AGs is the acquisition of AG-modifying enzymes (AMEs) by the bacteria, including AG N-acetyltransferases (AACs), AG O-phosphotransferases (APHs), and AG O-nucleotidyltransferases (ANTs). In this study, we obtained 122 multidrug-resistant P. aeruginosa clinical isolates and evaluated the antibacterial effects of six AGs and two carbapenems alone against all clinical isolates, and in combination against eight selected strains. We further probed for four representatives of the most common AME genes [aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia] by polymerase chain reaction (PCR) and compared the AME patterns of these 122 clinical isolates to their antibiotic resistance profile. Among the diverse antibiotics resistance profile displayed by these clinical isolates, we found correlations between the resistance to various AGs as well as between the resistance to one AG and the resistance to carbapenems. PCR results revealed that the presence of aac(6')-Ib renders these isolates more resistant to a variety of antibiotics. The correlation between resistance to various AGs and carbapenems partially reflects the complex resistance strategies adapted in these pathogens and encourages the development of strategic treatment for each P. aeruginosa infection by considering the genetic information of each isolated bacteria.

Entities:  

Keywords:  ESKAPE pathogens; aminoglycoside-modifying enzymes (AMEs); drug combination; resistance patterns

Mesh:

Substances:

Year:  2017        PMID: 29261405      PMCID: PMC6154764          DOI: 10.1089/mdr.2017.0101

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  53 in total

1.  A small molecule discrimination map of the antibiotic resistance kinome.

Authors:  Tushar Shakya; Peter J Stogios; Nicholas Waglechner; Elena Evdokimova; Linda Ejim; Jan E Blanchard; Andrew G McArthur; Alexei Savchenko; Gerard D Wright
Journal:  Chem Biol       Date:  2011-12-23

2.  Progress and challenges in implementing the research on ESKAPE pathogens.

Authors:  Louis B Rice
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

Review 3.  The changing epidemiology of resistance.

Authors:  Peter M Hawkey; Annie M Jones
Journal:  J Antimicrob Chemother       Date:  2009-09       Impact factor: 5.790

4.  In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.

Authors:  Luigi Principe; Alessandro Capone; Antonio Mazzarelli; Silvia D'Arezzo; Eugenio Bordi; Antonino Di Caro; Nicola Petrosillo
Journal:  Microb Drug Resist       Date:  2013-05-09       Impact factor: 3.431

5.  Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes.

Authors:  Jacob L Houghton; Keith D Green; Rachel E Pricer; Abdelrahman S Mayhoub; Sylvie Garneau-Tsodikova
Journal:  J Antimicrob Chemother       Date:  2012-12-11       Impact factor: 5.790

6.  Design, synthesis, and antibacterial activities of conformationally constrained kanamycin A derivatives.

Authors:  Wenxuan Zhang; Ying Chen; Qingzhao Liang; Hui Li; Hongwei Jin; Liangren Zhang; Xiangbao Meng; Zhongjun Li
Journal:  J Org Chem       Date:  2012-12-18       Impact factor: 4.354

7.  Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Authors:  Reem Almaghrabi; Cornelius J Clancy; Yohei Doi; Binghua Hao; Liang Chen; Ryan K Shields; Ellen G Press; Nicole M Iovine; Bethany M Townsend; Marilyn M Wagener; Barry Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

8.  Effects of altering aminoglycoside structures on bacterial resistance enzyme activities.

Authors:  Keith D Green; Wenjing Chen; Sylvie Garneau-Tsodikova
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

9.  Inhibition of AAC(6')-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2',4'-bridged nucleic acid-NC-DNA hybrid oligomer.

Authors:  Christina Lopez; Brock A Arivett; Luis A Actis; Marcelo E Tolmasky
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

10.  Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci.

Authors:  A Kropec; S Lemmen; M Wursthorn; F D Daschner
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

View more
  10 in total

1.  Analysis of the Pseudomonas aeruginosa Aminoglycoside Differential Resistomes Allows Defining Genes Simultaneously Involved in Intrinsic Antibiotic Resistance and Virulence.

Authors:  Fernando Sanz-García; Carolina Alvarez-Ortega; Jorge Olivares-Pacheco; Paula Blanco; José Luis Martínez; Sara Hernando-Amado
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 2.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

3.  Nucleoside triphosphate cosubstrates control the substrate profile and efficiency of aminoglycoside 3'-O-phosphotransferase type IIa.

Authors:  Selina Y L Holbrook; Matthew S Gentry; Oleg V Tsodikov; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2018-07-16       Impact factor: 3.597

4.  Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.

Authors:  Ragi Jadimurthy; Shilpa Borehalli Mayegowda; S Chandra Nayak; Chakrabhavi Dhananjaya Mohan; Kanchugarakoppal S Rangappa
Journal:  Biotechnol Rep (Amst)       Date:  2022-04-04

5.  Synthesis of saccharocin from apramycin and evaluation of its ribosomal selectivity.

Authors:  Vikram A Sarpe; Michael G Pirrone; Klara Haldimann; Sven N Hobbie; Andrea Vasella; David Crich
Journal:  Medchemcomm       Date:  2019-03-13       Impact factor: 3.597

6.  Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant.

Authors:  Jonathan C K Quirke; Parasuraman Rajasekaran; Vikram A Sarpe; Amr Sonousi; Ivan Osinnii; Marina Gysin; Klara Haldimann; Qiao-Jun Fang; Dimitri Shcherbakov; Sven N Hobbie; Su-Hua Sha; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich
Journal:  J Am Chem Soc       Date:  2019-12-17       Impact factor: 15.419

7.  Patterns of Drug-Resistant Bacteria in a General Hospital, China, 2011-2016.

Authors:  Tingting Mao; Huijuan Zhai; Guangcai Duan; Haiyan Yang
Journal:  Pol J Microbiol       Date:  2019

8.  Translation error clusters induced by aminoglycoside antibiotics.

Authors:  Ingo Wohlgemuth; Raffaella Garofalo; Ekaterina Samatova; Aybeg Nafiz Günenç; Christof Lenz; Henning Urlaub; Marina V Rodnina
Journal:  Nat Commun       Date:  2021-03-23       Impact factor: 14.919

Review 9.  Antibiotic Combination Therapy: A Strategy to Overcome Bacterial Resistance to Aminoglycoside Antibiotics.

Authors:  Nuoyan Wang; Jing Luo; Fei Deng; Yasi Huang; Hong Zhou
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

10.  Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.

Authors:  Chenyan Zhao; Anna Chirkova; Staffan Rosenborg; Rodrigo Palma Villar; Johan Lindberg; Sven N Hobbie; Lena E Friberg
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.